07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Pfizer deal

Pfizer will acquire AstraZeneca’s small molecule anti-infectives business. The unit includes approved drugs Zavicefta ceftazidime/ avibactam, Zinforo ceftaroline fosamil and Merrem/Meronem meropenam, as well as Phase II candidates, ATM-AVI and ...
07:00 , Aug 24, 2016 |  BC Extra  |  Company News

Pfizer buying AZ's small molecule anti-infectives business

Pfizer Inc. (NYSE:PFE) is acquiring the small molecule anti-infectives business of AstraZeneca plc (LSE:AZN; NYSE:AZN) for $550 million in cash up front and $175 million due in January 2019. The unit includes approved drugs Zavicefta...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Oral delafloxacin: Phase III data

Top-line data from the double-blind, international Phase III RX-3341-303 trial in 850 patients with ABSSSIs showed that IV-to-oral Baxdela met the FDA-defined primary endpoint of non-inferiority to standard of care (SOC) IV vancomycin plus aztreonam...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

IV Baxdela delafloxacin: Phase III data

Top-line data from the double-blind, international Phase III RX-3341-303 trial in 850 patients with ABSSSIs showed that IV-to-oral Baxdela met the FDA-defined primary endpoint of non-inferiority to standard of care (SOC) IV vancomycin plus aztreonam...
00:37 , May 13, 2016 |  BC Extra  |  Clinical News

Melinta's Baxdela passes second Phase III test

Melinta Therapeutics Inc. (New Haven, Conn.) said IV-to-oral Baxdela delafloxacin (RX-3341) was non-inferior to the standard-of-care regimen of vancomycin plus aztreonam, meeting the primary endpoints of a Phase III study to treat acute bacterial skin...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: E. coli DNA adenine methyltransferase (Dam)

Infectious disease INDICATION: Bacterial infection Cell studies suggest inhibiting E. coli Dam could help enhance the sensitivity of the bacterial infection to antibiotics. In a cultured strain of E. coli, knockout of Dam plus an antibiotic -...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Allergan deal

The companies partnered to develop and commercialize ATM-AVI to treat metallo-beta-lactamase-producing Gram-negative bacterial infections. Allergan will have commercialization rights in the U.S. and Canada, and AstraZeneca will retain rights in all other countries. ATM-AVI...
02:46 , Jan 30, 2016 |  BC Extra  |  Company News

Allergan, AZ partner to develop antibiotic

Allergan plc (NYSE:AGN) said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to develop ATM-AVI, a combination of antibiotics aztreonam and avibactam to treat Gram-negative infections. ATM-AVI was developed under a partnership between AZ and the...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

IV delafloxacin: Additional Phase III data

Additional data from the double-blind, international Phase III Study RX-3341-302 in 660 patients with ABSSSIs showed that 300 mg IV delafloxacin given every 12 hours for 5-14 days led to an objective response in 78.2%...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

AstraZeneca, U.S. Department of Health and Human Services infectious news

AstraZeneca said HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded the company a five-year contract with a total potential value of $170 million to develop a portfolio of drug candidates to treat illnesses caused...